In this webinar, Dr Ian Porter explores Rhenium-SCT® for the treatment of non-melanoma skin cancers (NMSCs).
Delivered in collaboration with OncoBeta, this webinar explores the clinical application of non-invasive, single-session epidermal radioisotope therapy using rhenium-188 for the treatment of NMSC.
Dr Ian Porter presents key clinical data, including the 12-month interim results from the EPIC phase IV efficacy study, which includes international and Australian patient cohorts. He also shares practical insights through real-world case studies and patient outcomes.
This session is designed for medical professionals interested in expanding their understanding of emerging treatment options now available in Australia. Helpful resources also included below!
We invite you to download the:
🎓 Micro-Courses in Skin Cancer
Explore short, bite-sized CPD modules in focused topics in skin cancer. Complete in less than 10 hours from only $95.
➡️ Browse Micro-Courses >
🎓 Certificate Courses in Skin Cancer
Explore our university-assured, structured pathway to elevate your knowledge in the diagnosis and treatment of skin cancer.
➡️ Explore full program >
🎓 HealthCert 365 subscription
Prefer flexible, all-access learning across many topics? Access 4,000+ CPD hours on-demand with HealthCert 365 — an annual subscription for one flat fee.
➡️ Discover HealthCert 365 >
Or explore more educational content in Skin Cancer Medicine.
You can self-record CPD for this webinar. If you consume educational content on this blog, you can Quick Log CPD hours with the RACGP/ACRRM via the usual self-submission process. You will be asked to reflect on what you have learned, and you will require supporting evidence such as a screenshot. For more information, view the: RACGP CPD guide | ACRRM CPD guide
Dr Ian Porter completed his undergraduate medical degree at The University of Queensland and subsequently his FRANZCR Fellowship in Radiation Oncology at the Queensland Radium Institute and The William Buckland Radiotherapy Centre at Alfred Health in Melbourne. He provides a consultation Radiation Oncology service at Cabrini Malvern and Brighton, and is the inaugural Director of Radiation Oncology at Cabrini Health with a team of Radiation Technologists, Medical Physicists and Radiation Oncology Nurses. Dr Porter was the first in Australia to use adaptive radiation therapy to target organs that move. He is also a trials investigator with the Australasian TROG research group, an NHMRC Associate Investigator and an Adjunct Senior Lecturer at Monash University.